All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F20%3A00079666" target="_blank" >RIV/00023001:_____/20:00079666 - isvavai.cz</a>

  • Alternative codes found

    RIV/00023884:_____/20:00008690

  • Result on the web

    <a href="https://reader.elsevier.com/reader/sd/pii/S0002870320300272?token=E3F4B98F08F79A262F987A4873934BB2591489F5D4393005DFB4FAAD1E7898B363F7A6CC0C2A94846B21DE47A68DEA16" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0002870320300272?token=E3F4B98F08F79A262F987A4873934BB2591489F5D4393005DFB4FAAD1E7898B363F7A6CC0C2A94846B21DE47A68DEA16</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.ahj.2020.01.012" target="_blank" >10.1016/j.ahj.2020.01.012</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial

  • Original language description

    Background: Adverse cardiac remodeling is a major risk factor for the development of post myocardial infarction (MI) heart failure (HF). This study investigates the effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute ST-segment-elevation myocardial infarction (STEMI). Methods: In this double-blind, randomized, placebo-controlled trial patients with first STEMI were eligible. To preferentially enrich patients at high risk of adverse remodeling, main inclusion criteria were a left-ventricular ejection fraction (LVEF) ≤45% and an infarct size &gt;10% on day 5 to 9 post MI as measured by cardiac MRI. Patients were then randomized to 6 months treatment with either 25 mg fulacimstat (n = 54) or placebo (n = 53) twice daily on top of standard of care starting day 6 to 12 post MI. The changes in LVEF, LV end-diastolic volume index (LVEDVI), and LV end-systolic volume index (LVESVI) from baseline to 6 months were analyzed by a central blinded cardiac MRI core laboratory. Results: Fulacimstat was safe and well tolerated and achieved mean total trough concentrations that were approximately tenfold higher than those predicted to be required for minimal therapeutic activity. Comparable changes in LVEF (fulacimstat: 3.5% ± 5.4%, placebo: 4.0% ± 5.0%, P = .69), LVEDVI (fulacimstat: 7.3 ± 13.3 mL/m2, placebo: 5.1 ± 18.9 mL/m2, P = .54), and LVESVI (fulacimstat: 2.3 ± 11.2 mL/m2, placebo: 0.6 ± 14.8 mL/m2, P = .56) were observed in both treatment arms. Conclusion: Fulacimstat was safe and well tolerated in patients with left-ventricular dysfunction (LVD) after first STEMI but had no effect on cardiac remodeling. © 2020 Elsevier Inc.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    American heart journal

  • ISSN

    0002-8703

  • e-ISSN

  • Volume of the periodical

    224

  • Issue of the periodical within the volume

    June 2020

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    9

  • Pages from-to

    129-137

  • UT code for WoS article

    000540371700015

  • EID of the result in the Scopus database

    2-s2.0-85084081354